Charting the molecular network of the drug target Bcr-Abl.

@article{Brehme2009ChartingTM,
  title={Charting the molecular network of the drug target Bcr-Abl.},
  author={Marc Brehme and Oliver Hantschel and Jacques Colinge and Ines Kaupe and Melanie Planyavsky and Thomas K{\"o}cher and Karl Mechtler and Keiryn L. Bennett and Giulio Superti-Furga},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2009},
  volume={106 18},
  pages={7414-9}
}
The tyrosine kinase Bcr-Abl causes chronic myeloid leukemia and is the cognate target of tyrosine kinase inhibitors like imatinib. We have charted the protein-protein interaction network of Bcr-Abl by a 2-pronged approach. Using a monoclonal antibody we have first purified endogenous Bcr-Abl protein complexes from the CML K562 cell line and characterized the set of most tightly-associated interactors by MS. Nine interactors were subsequently subjected to tandem affinity purifications/MS… CONTINUE READING
65 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

The chemokine IL - 8 and the surface activation protein CD 69 are markers for Bcr - Abl activity in CML

  • O Hantschel
  • Molecular Oncology
  • 2008

The chemokine IL-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in CML. Molecular Oncology 2(3):272–281

  • O Hantschel
  • Brehme et al. PNAS May
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…